(Q40843184)

24 September 2017

1 reference

title

Advances in the treatment of herpesvirus infection: the role of famciclovir (English)

1 reference

24 September 2017

S K Tyring

1

1 reference

24 September 2017

publication date

1 July 1998

1 reference

24 September 2017

published in

Clinical Therapeutics

1 reference

24 September 2017

volume

20

1 reference

24 September 2017

issue

4

1 reference

24 September 2017

page(s)

661-670

1 reference

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Pharmacokinetics of acyclovir after intravenous and oral administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Safety of famciclovir in patients with herpes zoster and genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Shingles. Sorrows, salves, and solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Acute herpetic and postherpetic neuralgia: clinical review and current management

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

NIH conference. Herpes zoster-varicella infections in immunosuppressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Herpes zoster and postherpetic neuralgia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Herpes zoster: a possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

The natural history of herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

NIH Conference. Herpes simplex virus infection: biology, treatment, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Genital herpes simplex virus infections: clinical manifestations, course, and complications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Genital herpes simplex virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Subclinical shedding of HSV: its potential for reduction by antiviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980129-X

7 January 2021

10.1016/S0149-2918(98)80129-X

Identifiers

DOI

1 reference

24 September 2017

1 reference